ES2952159T3 - Minoxidil oral para el tratamiento de alopecia areata - Google Patents
Minoxidil oral para el tratamiento de alopecia areata Download PDFInfo
- Publication number
- ES2952159T3 ES2952159T3 ES19205898T ES19205898T ES2952159T3 ES 2952159 T3 ES2952159 T3 ES 2952159T3 ES 19205898 T ES19205898 T ES 19205898T ES 19205898 T ES19205898 T ES 19205898T ES 2952159 T3 ES2952159 T3 ES 2952159T3
- Authority
- ES
- Spain
- Prior art keywords
- approximately
- minoxidil
- range
- hair
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 title claims abstract description 90
- 229960003632 minoxidil Drugs 0.000 title claims abstract description 89
- 238000011282 treatment Methods 0.000 title claims description 66
- 208000004631 alopecia areata Diseases 0.000 title claims description 23
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 22
- 229960002256 spironolactone Drugs 0.000 claims description 22
- 230000002265 prevention Effects 0.000 claims description 17
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 claims description 11
- 239000011780 sodium chloride Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 claims description 9
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 claims description 8
- 229960000978 cyproterone acetate Drugs 0.000 claims description 8
- 229960004039 finasteride Drugs 0.000 claims description 8
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims description 8
- 229960002074 flutamide Drugs 0.000 claims description 8
- 229960004199 dutasteride Drugs 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 claims description 5
- 230000002280 anti-androgenic effect Effects 0.000 claims description 5
- 239000000051 antiandrogen Substances 0.000 claims description 5
- HJBWBFZLDZWPHF-UHFFFAOYSA-N apalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S HJBWBFZLDZWPHF-UHFFFAOYSA-N 0.000 claims description 5
- 229950007511 apalutamide Drugs 0.000 claims description 5
- 229960000997 bicalutamide Drugs 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 claims description 5
- 229960004671 enzalutamide Drugs 0.000 claims description 5
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 claims description 5
- 229960002653 nilutamide Drugs 0.000 claims description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 4
- 239000011701 zinc Substances 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- 229940123934 Reductase inhibitor Drugs 0.000 claims description 3
- 229940083712 aldosterone antagonist Drugs 0.000 claims description 3
- 239000002170 aldosterone antagonist Substances 0.000 claims description 3
- 239000003956 nonsteroidal anti androgen Substances 0.000 claims description 3
- 240000004670 Glycyrrhiza echinata Species 0.000 claims description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 229960001948 caffeine Drugs 0.000 claims description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 2
- 229940010454 licorice Drugs 0.000 claims description 2
- 239000011669 selenium Substances 0.000 claims description 2
- 229910052711 selenium Inorganic materials 0.000 claims description 2
- 230000003637 steroidlike Effects 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 201000004384 Alopecia Diseases 0.000 abstract description 157
- 230000003676 hair loss Effects 0.000 abstract description 134
- 208000024963 hair loss Diseases 0.000 abstract description 131
- 208000003024 Diffuse alopecia Diseases 0.000 abstract description 18
- 201000001297 telogen effluvium Diseases 0.000 abstract description 18
- 238000000034 method Methods 0.000 abstract description 15
- 210000004209 hair Anatomy 0.000 description 118
- 230000003645 female-pattern hair loss Effects 0.000 description 36
- 230000000007 visual effect Effects 0.000 description 34
- 210000004761 scalp Anatomy 0.000 description 20
- 206010068168 androgenetic alopecia Diseases 0.000 description 17
- 201000002996 androgenic alopecia Diseases 0.000 description 15
- 230000000699 topical effect Effects 0.000 description 15
- 230000036772 blood pressure Effects 0.000 description 13
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 230000009467 reduction Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 230000006872 improvement Effects 0.000 description 8
- 230000001684 chronic effect Effects 0.000 description 7
- 210000003780 hair follicle Anatomy 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 206010020864 Hypertrichosis Diseases 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 230000003273 male-pattern hair loss Effects 0.000 description 6
- 238000012552 review Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 230000005856 abnormality Effects 0.000 description 5
- 230000003698 anagen phase Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000001815 facial effect Effects 0.000 description 5
- 230000003797 telogen phase Effects 0.000 description 5
- 208000002720 Malnutrition Diseases 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 231100000360 alopecia Toxicity 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 240000002132 Beaucarnea recurvata Species 0.000 description 3
- 208000024780 Urticaria Diseases 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 238000009534 blood test Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000003721 exogen phase Effects 0.000 description 3
- 230000003803 hair density Effects 0.000 description 3
- 230000003779 hair growth Effects 0.000 description 3
- 230000003741 hair volume Effects 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000001144 postural effect Effects 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000003813 thin hair Effects 0.000 description 3
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 2
- 208000002682 Hyperkalemia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 206010066295 Keratosis pilaris Diseases 0.000 description 2
- 238000000585 Mann–Whitney U test Methods 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- ZRWPUFFVAOMMNM-UHFFFAOYSA-N Patulin Chemical compound OC1OCC=C2OC(=O)C=C12 ZRWPUFFVAOMMNM-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 208000012886 Vertigo Diseases 0.000 description 2
- 229960003473 androstanolone Drugs 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000003659 hair regrowth Effects 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 208000003532 hypothyroidism Diseases 0.000 description 2
- 230000002989 hypothyroidism Effects 0.000 description 2
- 230000016507 interphase Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 238000007449 liver function test Methods 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 235000018343 nutrient deficiency Nutrition 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 2
- 229940117382 propecia Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 150000003431 steroids Chemical group 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 231100000889 vertigo Toxicity 0.000 description 2
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 206010001764 Alopecia scarring Diseases 0.000 description 1
- 229940123407 Androgen receptor antagonist Drugs 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102100034573 Desmoglein-4 Human genes 0.000 description 1
- 101710183213 Desmoglein-4 Proteins 0.000 description 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 101001007027 Homo sapiens Keratin, type II cuticular Hb1 Proteins 0.000 description 1
- 101001026976 Homo sapiens Keratin, type II cuticular Hb3 Proteins 0.000 description 1
- 101001026977 Homo sapiens Keratin, type II cuticular Hb6 Proteins 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 201000009495 Hypotrichosis Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 102100028340 Keratin, type II cuticular Hb1 Human genes 0.000 description 1
- 102100037379 Keratin, type II cuticular Hb3 Human genes 0.000 description 1
- 102100037382 Keratin, type II cuticular Hb6 Human genes 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 229940122767 Potassium sparing diuretic Drugs 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 206010044625 Trichorrhexis Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940092229 aldactone Drugs 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 239000003936 androgen receptor antagonist Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 229940054749 avodart Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- AQIXAKUUQRKLND-UHFFFAOYSA-N cimetidine Chemical compound N#C/N=C(/NC)NCCSCC=1N=CNC=1C AQIXAKUUQRKLND-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 108091008053 gene clusters Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004919 hair shaft Anatomy 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000005195 occipital scalp Anatomy 0.000 description 1
- 229940100691 oral capsule Drugs 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000003234 polygenic effect Effects 0.000 description 1
- 239000003286 potassium sparing diuretic agent Substances 0.000 description 1
- 229940097241 potassium-sparing diuretic Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 238000004018 waxing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Inorganic Chemistry (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2014904327A AU2014904327A0 (en) | 2014-10-29 | Detection and treatment of excessive hair shedding |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2952159T3 true ES2952159T3 (es) | 2023-10-27 |
Family
ID=55856287
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19205898T Active ES2952159T3 (es) | 2014-10-29 | 2015-10-29 | Minoxidil oral para el tratamiento de alopecia areata |
| ES15854489T Active ES2773467T3 (es) | 2014-10-29 | 2015-10-29 | Minoxidil oral para el tratamiento del efluvio telógeno |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15854489T Active ES2773467T3 (es) | 2014-10-29 | 2015-10-29 | Minoxidil oral para el tratamiento del efluvio telógeno |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10226462B2 (enExample) |
| EP (2) | EP3626244B1 (enExample) |
| JP (2) | JP6915946B2 (enExample) |
| KR (2) | KR20240011239A (enExample) |
| CN (2) | CN107106560A (enExample) |
| AU (4) | AU2015337807B2 (enExample) |
| CA (2) | CA3209849A1 (enExample) |
| ES (2) | ES2952159T3 (enExample) |
| NZ (1) | NZ732075A (enExample) |
| SG (2) | SG10202002705YA (enExample) |
| WO (1) | WO2016065426A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2952159T3 (es) | 2014-10-29 | 2023-10-27 | Samson Clinical Pty Ltd | Minoxidil oral para el tratamiento de alopecia areata |
| BR112019010131A2 (pt) | 2016-11-21 | 2019-10-08 | Eirion Therapeutics Inc | entrega transdérmica de agentes grandes |
| US20180189976A1 (en) | 2016-12-29 | 2018-07-05 | Michal Kasprzak | Analysis unit and system for assessment of hair condition |
| KR102663164B1 (ko) * | 2017-07-12 | 2024-05-07 | 삼손 클리니컬 피티와이 엘티디 | 모발 성장을 촉진시키고, 탈모 또는 과도한 머리카락 빠짐의 치료 |
| EP3849540A1 (en) * | 2018-09-13 | 2021-07-21 | Eirion Therapeutics, Inc. | Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors |
| CN109674762A (zh) * | 2019-03-05 | 2019-04-26 | 南京正大天晴制药有限公司 | 一种度他雄胺及治疗脱发的组合物胶囊 |
| CN110478450B (zh) * | 2019-10-09 | 2021-04-13 | 北海鑫臻药业有限公司 | 一种治疗阿尔茨海默病的药物组合物及其应用 |
| CN111110721A (zh) * | 2020-01-19 | 2020-05-08 | 朱炜 | 一种毛发防脱再生的复合制剂及其使用方法 |
| WO2021172060A1 (ja) * | 2020-02-27 | 2021-09-02 | パナソニックＩｐマネジメント株式会社 | 画像処理装置及び画像処理方法 |
| CA3233426A1 (en) * | 2021-09-29 | 2023-04-06 | Animesh SINHA | Hair loss therapy |
| US11744788B2 (en) * | 2021-10-27 | 2023-09-05 | James D. Welch | Method of encouraging growth and regrowth of hair in human males technical area |
| EP4608405A1 (en) | 2022-10-25 | 2025-09-03 | Veradermics, Incorporated | Compositions and methods of use for modified release minoxidil |
| AU2023361983A1 (en) * | 2023-09-01 | 2025-03-20 | Follea International | Compositions and methods for an oral supplement to oral minoxidil for the treatment of alopecia |
| US20250213594A1 (en) * | 2023-12-27 | 2025-07-03 | Inventage Lab Inc. | Novel long-acting injectable composition for preventing or treating androgenetic alopecia containing finasteride |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4997643A (en) | 1989-07-12 | 1991-03-05 | Union Carbide Chemicals And Plastics Company Inc. | Polymeric salt delivery systems |
| JPH06501947A (ja) * | 1990-11-14 | 1994-03-03 | ジ・アップジョン・カンパニー | ５−フルオロ−２，４，６−ピリミジントリアミン化合物 |
| US5407944A (en) * | 1993-02-19 | 1995-04-18 | Goldman; Boris E. | Compositions and methods for promoting hair growth |
| GB2314019B (en) * | 1996-06-10 | 2000-03-15 | Bio Scient Ltd | The use of L-Lysine in the treatment of hair loss |
| WO1999040898A2 (en) | 1998-02-12 | 1999-08-19 | Centrapharm Inc. | Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect |
| JP2000038340A (ja) | 1998-05-20 | 2000-02-08 | Kumahiro Miyama | 育毛剤および食品 |
| JP2003012542A (ja) | 2001-06-26 | 2003-01-15 | Toray Ind Inc | 発毛促進剤 |
| US20050271596A1 (en) | 2002-10-25 | 2005-12-08 | Foamix Ltd. | Vasoactive kit and composition and uses thereof |
| DE102004023069A1 (de) * | 2004-05-11 | 2005-12-08 | Bayer Healthcare Ag | Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil |
| RU2357758C2 (ru) | 2004-10-07 | 2009-06-10 | Кабусики Кайся Санги | Препараты для чрескожной и чресслизистой доставки |
| US20080064765A1 (en) * | 2006-09-11 | 2008-03-13 | Jacob Birnbaum | Novel hair growth compositions and methods for treating hair loss or related claims |
| US8110655B2 (en) * | 2006-11-13 | 2012-02-07 | Auxagen, Inc. | Method to promote hair growth and/or delay or treat hair loss by administering a TGF-β antagonist or inhibitor |
| WO2010036947A2 (en) | 2008-09-27 | 2010-04-01 | Jina Pharmaceuticals, Inc. | Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof |
| US8691518B2 (en) * | 2010-09-24 | 2014-04-08 | Global Life Science Partners Limited | Systems and methods for predicting response to minoxidil for the treatment of androgenetic alopecia |
| EP2510930A1 (en) | 2011-04-15 | 2012-10-17 | Bionanoplus, S.L. | Nanoparticles comprising half esters of poly (methyl vinyl ether-co-maleic anhydride) and uses thereof |
| AU2011100917B4 (en) * | 2011-07-26 | 2013-05-02 | Sinclair, Rodney Daniel Professor | Treatment of male and female androgenetic alopecia with oral minoxidil either alone or in combination with antiandrogens |
| WO2013181487A2 (en) | 2012-05-31 | 2013-12-05 | Stiefel Laboratories, Inc. | Method of treating |
| ES2952159T3 (es) | 2014-10-29 | 2023-10-27 | Samson Clinical Pty Ltd | Minoxidil oral para el tratamiento de alopecia areata |
| US9561224B1 (en) | 2015-05-27 | 2017-02-07 | Moshe Rogosnitzky | Methods and compositions for treating androgenetic alopecia |
| KR102663164B1 (ko) | 2017-07-12 | 2024-05-07 | 삼손 클리니컬 피티와이 엘티디 | 모발 성장을 촉진시키고, 탈모 또는 과도한 머리카락 빠짐의 치료 |
-
2015
- 2015-10-29 ES ES19205898T patent/ES2952159T3/es active Active
- 2015-10-29 KR KR1020247000993A patent/KR20240011239A/ko not_active Ceased
- 2015-10-29 US US15/522,599 patent/US10226462B2/en active Active
- 2015-10-29 NZ NZ732075A patent/NZ732075A/en unknown
- 2015-10-29 CA CA3209849A patent/CA3209849A1/en active Pending
- 2015-10-29 EP EP19205898.0A patent/EP3626244B1/en active Active
- 2015-10-29 SG SG10202002705YA patent/SG10202002705YA/en unknown
- 2015-10-29 AU AU2015337807A patent/AU2015337807B2/en active Active
- 2015-10-29 CN CN201580061561.5A patent/CN107106560A/zh active Pending
- 2015-10-29 WO PCT/AU2015/050682 patent/WO2016065426A1/en not_active Ceased
- 2015-10-29 SG SG11201703424WA patent/SG11201703424WA/en unknown
- 2015-10-29 CN CN202310057359.1A patent/CN115998740A/zh active Pending
- 2015-10-29 EP EP15854489.0A patent/EP3212192B1/en active Active
- 2015-10-29 KR KR1020177014272A patent/KR102625061B1/ko active Active
- 2015-10-29 ES ES15854489T patent/ES2773467T3/es active Active
- 2015-10-29 JP JP2017542212A patent/JP6915946B2/ja active Active
- 2015-10-29 CA CA3003940A patent/CA3003940C/en active Active
-
2017
- 2017-08-01 AU AU2017210523A patent/AU2017210523B2/en active Active
-
2018
- 2018-12-17 AU AU2018279055A patent/AU2018279055A1/en not_active Abandoned
-
2019
- 2019-01-18 US US16/252,107 patent/US11116770B2/en active Active
-
2020
- 2020-04-03 JP JP2020067194A patent/JP2020109127A/ja active Pending
- 2020-06-04 AU AU2020203695A patent/AU2020203695B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2952159T3 (es) | Minoxidil oral para el tratamiento de alopecia areata | |
| Glynis | A double-blind, placebo-controlled study evaluating the efficacy of an oral supplement in women with self-perceived thinning hair | |
| Raffi et al. | Clinical recognition and management of alopecia in women of color | |
| Nichols et al. | An open-label evaluator blinded study of the efficacy and safety of a new nutritional supplement in androgenetic alopecia: a pilot study | |
| Torres | Androgenetic, diffuse and senescent alopecia in men: practical evaluation and management | |
| Rivitti | Alopecia areata: a revision and update | |
| Buch et al. | Approach to inherited hypertrichosis: A brief review | |
| Goldberg et al. | Alopecia: Kids are not just little people | |
| HK40023042A (en) | Oral minoxidil for the treatment of alopecia areata | |
| HK40023042B (en) | Oral minoxidil for the treatment of alopecia areata | |
| HK1243641B (en) | Oral minoxidil for the treatment of telogen effluvium | |
| Islam et al. | A guide to diagnosis and management of hypertrichosis | |
| Thuangtong et al. | A Comparative Study between the Efficacy and Safety of 5% Minoxidil Solution and 5% Minoxidil Milky Lotion in the Treatment of Male Androgenic Alopecia. | |
| Katoulis et al. | Frontal fibrosing alopecia | |
| Anastassakis | Diagnostic Steps in the Evaluation of AGA/FPHL | |
| Purvis et al. | Hair & Nails | |
| Elias et al. | BG02 A case of Werner syndrome: undiagnosed progeroid syndrome presenting as female pattern hair loss | |
| Tej | Clinical and Epidemiological Study of Alopecia Areata | |
| de Oliveira | Community Pharmacy and Hospital Pharmacy Internship Reports and Monograph" Counseling for Androgenetic Alopecia-The Pharmacist's Role" | |
| Srilakshmi | Clinico-Epidemiological Study of Alopecias in Females in Correlation with Serum Ferritin, Vitamin B12 and Thyroid Profile |